In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide

MLA

Tingyu Li, et al. “In Vivo and in Vitro Inhibition of SCLC by Combining Dual Cancer-Specific Recombinant Adenovirus with Etoposide.” Journal of Cancer Research and Clinical Oncology, vol. 148, Jan. 2022, pp. 1073–85. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4ff1f10a3d667b5657e57c3365b6c6d3&authtype=sso&custid=ns315887.

APA

Tingyu Li, Jinbo Fang, Jihao Chu, Xing Liu, Yiquan Li, Yilong Zhu, Shanzhi Li, Zhiru Xiu, Yaru Li, Ningyi Jin, Guangzhe Zhu, Lili Sun, & Xiao Li. (2022). In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide. Journal of Cancer Research and Clinical Oncology, 148, 1073–1085.

Chicago

Tingyu Li, Jinbo Fang, Jihao Chu, Xing Liu, Yiquan Li, Yilong Zhu, Shanzhi Li, et al. 2022. “In Vivo and in Vitro Inhibition of SCLC by Combining Dual Cancer-Specific Recombinant Adenovirus with Etoposide.” Journal of Cancer Research and Clinical Oncology 148 (January): 1073–85. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4ff1f10a3d667b5657e57c3365b6c6d3&authtype=sso&custid=ns315887.